Patent application number | Description | Published |
20090275519 | Therapeutic peptidomimetic macrocycles - The present invention provides biologically active peptidomimetic macrocycles for the treatment of cell proliferative disorders such as cancer and immunoproliferative disease. | 11-05-2009 |
20100047257 | ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER - Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the A class of Eph receptors. | 02-25-2010 |
20120101047 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. | 04-26-2012 |
20120115783 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. | 05-10-2012 |
20120115793 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. | 05-10-2012 |
20120149648 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active peptidomimetic macrocycles for the treatment of cell proliferative disorders such as cancer and immunoproliferative disease. | 06-14-2012 |
20120178700 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. | 07-12-2012 |
20150038430 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active peptidomimetic macrocycles for the treatment of cell proliferative disorders such as cancer and immunoproliferative disease. | 02-05-2015 |
Patent application number | Description | Published |
20090120796 | ELECTROKINETIC CONCENTRATION DEVICE AND METHODS OF USE THEREOF - The present invention provides a device and methods of use thereof in concentrating a species of interest and/or controlling liquid flow in a device. The methods, inter-alia, make use of a device comprising a fluidic chip comprising a planar array of channels through which a liquid comprising a species of interest can be made to pass with at least one rigid substrate connected thereto such that at least a portion of a surface of the substrate bounds the channels, and an ion-selective membrane is attached to at least a portion of the surface of the substrate, which bounds said channels, or which bounds a portion of a surface of one of said channels. The device comprises a unit to induce an electric field in the channel and a unit to induce an electrokinetic or pressure driven flow in the channel. | 05-14-2009 |
20090136948 | NANOCONFINEMENT- BASED DEVICES AND METHODS OF USE THEREOF - The present invention provides a device/kit and methods of use thereof in rapid detection of target molecule binding to a cognate binding partner. The methods, inter-alia, make use of a device comprising channels or reservoirs, which are linked to nanochannels, whereby upon application of the cognate binding partner to the nanochannel comprising the target molecule under flow, a detectable change in conductance, capacitance or fluorescence or surface potential occurs. | 05-28-2009 |
20090176315 | Microfluidic pl-based molecular sorting - This invention is directed to methods and devices for separating molecules in a sample, based on differences in their isoelectric point (pI). The methods and devices make use of a diffusion potential created in a microfluidic chamber when a buffered solution comprising molecules, which differ in terms of their isoelectric point (pI) values and a second buffer, which differs from the buffered solution in terms of its pH or salt concentration are introduced in the chamber. The diffusion potential, in turn, enables charge-based separation of the molecules. Applications and permutations of the methods and devices are described. | 07-09-2009 |
20090242406 | METHODS FOR FABRICATING ELECTROKINETIC CONCENTRATION DEVICES - The present invention provides a device and methods of use thereof in concentrating a species of interest and/or controlling liquid flow in a device. The methods make use of a device comprising a fluidic chip comprising a planar array of channels through which a liquid comprising a species of interest can be made to pass with at least one rigid substrate connected thereto such that at least a portion of a surface of the substrate bounds the channels, and a high aspect ratio ion-selective membrane is embedded within the chip, attached to at least a portion of the channels. The device comprises a unit to induce an electric field in the channel and a unit to induce an electrokinetic or pressure driven flow in the channel. | 10-01-2009 |
20100187112 | NANOFLUIDIC PRECONCENTRATION DEVICE IN AN OPEN ENVIRONMENT - This invention provides a device and methods for increasing the concentration of a charged species in solution, wherein the solution containing the concentrated species is exposed to the environment. Such solution can be formed on a surface or on a tip of a measurement device. The open-environment concentration technique overcomes the disadvantages of in-channel concentration devices, especially by eliminating flow-induced delivery processes that lead to concentration losses. Combined with direct contact dispensing, methods of this invention can be used for various applications such as immunoassay and MALDI-MS. | 07-29-2010 |
20110081674 | CONTINUOUS-FLOW DEFORMABILITY-BASED CELL SEPARATION - This invention provides methods utilizing a microfluidic device that can quickly and accurately discern differences in deformability between individual cells and sets of cells and continuously fractionate populations of cells based on their deformability. This information may be important in disease diagnosis and treatment efficacy monitoring. For example such a device may be able to determine the stage of malarial infection by using red blood cell deformability. Additionally, methods of the invention may be used as a tool to screen drugs that can make cells more flexible in diseases such as sickle cell anemia that causes sickle cell crises. The relatively low manufacturing and operation costs of methods of the invention enable this device to be used in resource-limited settings to diagnose and monitor disease. | 04-07-2011 |
20110114486 | CONTINUOUS BIOMOLECULE SEPARATION IN A NANOFILTER - This invention provides a method and an apparatus for quickly continuously fractionating biomolecules, such as DNAs, proteins and carbohydrates by taking advantage of differential bidirectional transport of biomolecules with varying physico-chemical characteristics, for example size, charge, hydrophobicity, or combinations thereof, through periodic arrays of microfabricated nanofilters. The passage of biomolecules through the nanofilter is a function of both steric and electrostatic interactions between charged macromolecules and charged nanofilter walls, Continuous-flow separation through the devices of this invention are applicable for molecules varying in terms of any molecular properties (e.g., size, charge density or hydrophobicity) that can lead to differential transport across the nanofilters. | 05-19-2011 |
20110198225 | AMPLIFIED ELECTROKINETIC FLUID PUMPING SWITCHING AND DESALTING - The present invention provides a device and methods of use thereof for desalting a solution. The methods, inter-alia, make use of a device comprising microchannels, which are linked to conduits, whereby induction of an electric field in the conduit results in the formation of a space charge layer within the microchannel. The space charge layer provides an energy barrier for salt ions and generates an ion depletion zone proximal to the linkage region between the microchannel and the conduit. The method thus enables the removal of salt ions from the region proximal to the conduit and their accumulation in a region distant from the conduit, within the microchannel. | 08-18-2011 |
20110220498 | Method for Building Massively-Parallel Preconcentration Device for Multiplexed, High-Throughput Applications - A multiplexed concentration interface that can connect with a plurality of microchannels, conventional 96 well plates or other microarrays is disclosed. The interface can be used in biosensing platforms and can be designed to detect single or multiple targets such as DNA/RNA, proteins and carbohydrates/oligosaccharides. The multiplexed concentration device will provide a set of volume-matched sample preparation and detection strategies directly applicable by ordinary researchers. Furthermore, a multiplexed microfluidic concentrator without buffer channels is disclosed. | 09-15-2011 |
20110251652 | NEURAL PROSTHETICS USING A CHEMICAL HARVESTING AND STIMULATION DEVICE - A neural prosthetic device is provided that includes one or more ion-selective membranes enabling electrically-controlled local modulation of ion concentrations around a nerve so as to achieve different excitability states of the nerve for electrical stimulation or inhibition of nerve signal propagation. | 10-13-2011 |
20120064505 | MEASUREMENT OF MATERIAL PROPERTIES AND RELATED METHODS AND COMPOSITIONS - The invention in some aspects relates to methods, devices and compositions for evaluating material properties, such as mechanical and rheological properties of substances, particularly biological substances, such as cells, tissues, and biological fluids. In some aspects, the invention relates to methods, devices and compositions for evaluating material properties of deformable objects, such as cells. In further aspects, the invention relates to methods, devices and compositions for diagnosing and/or characterizing disease based on material properties of biological cells. | 03-15-2012 |
20120247979 | Method for Enhancing Current Throughput in an Electrochemical System - An electrochemical system with reduced limiting-current behavior is disclosed. The electrochemical system is useful for fuel cells and bio-sensors. In part, the invention relates a method of reducing or eliminating limiting-current behavior in the operation electrochemical systems, in particular those with ion-selective membrane or electrochemical electrodes, by spatially reducing the convection near the membrane or the electrode. The invention further relates to electrochemical systems in which micropores, microarrays or pillar arrays are used to reduce convection in comparison to conventional systems without microarrays, micropores or pillar arrays. | 10-04-2012 |
20120315596 | SYSTEMS AND METHODS FOR DELIVERING SUBSTANCES INTO NANOPOROUS MINERALIZED TISSUES - Methods and systems are provided for transporting a therapeutic or cosmetic substance into nanoporous mineralized tissue structures, such as teeth. The method may include contacting the nanoporous mineralized tissue structure with an ionic solution including the therapeutic or cosmetic substance; and simultaneously applying to the nanoporous mineralized tissue structure an electrical potential effective to transport the therapeutic or cosmetic substance into the nanopores of the nanoporous mineralized tissue structure. The system may include at least one pair of electrodes which includes a first electrode configured for contacting the nanoporous mineralized tissue structure and a second electrode; and a power source and control circuitry for generating an electrical potential between the first electrode and the second electrode effective to transport a therapeutic or cosmetic substance, in an ionic solution in contact with a surface of the nanoporous mineralized tissue structure, into the nanopores of the nanoporous mineralized tissue structure. | 12-13-2012 |
20130030510 | MICROFABRICATED ION-SELECTIVE ELECTRODES FOR FUNCTIONAL ELECTRICAL STIMULATION AND NEURAL BLOCKING - A neural prosthetic device is provided that includes one or more ion-selective membranes enabled by electrically-controlled local modulation of ion concentrations around a nerve so as to achieve different excitability states of the nerve for electrical stimulation or inhibition of nerve signal propagation. The local modulation is achieved by positioning the nerve in a bipolar perpendicular arrangement so as to modulate the ion concentrations of the one or more ion-selective membranes in situ to change the nerve excitability locally at the site of electrical stimulation or along the nerve for on-demand suppression of nerve propagation. | 01-31-2013 |
20130256134 | METHODS FOR FABRICATING ELECTROKINETIC CONCENTRATION DEVICES - The present invention provides a device and methods of use thereof in concentrating a species of interest and/or controlling liquid flow in a device. The methods make use of a device comprising a fluidic chip comprising a planar array of channels through which a liquid comprising a species of interest can be made to pass with at least one rigid substrate connected thereto such that at least a portion of a surface of the substrate bounds the channels, and a high aspect ratio ion-selective membrane is embedded within the chip, attached to at least a portion of the channels. The device comprises a unit to induce an electric field in the channel and a unit to induce an electrokinetic or pressure driven flow in the channel. | 10-03-2013 |
20140322630 | Method for Enhancing Current Throughput in an Electrochemical System - An electrochemical system with reduced limiting-current behavior is disclosed. The electrochemical system is useful for fuel cells and bio-sensors. In part, the invention relates a method of reducing or eliminating limiting-current behavior in the operation electrochemical systems, in particular those with ion-selective membrane or electrochemical electrodes, by spatially reducing the convection near the membrane or the electrode. The invention further relates to electrochemical systems in which micropores, microarrays or pillar arrays are used to reduce convection in comparison to conventional systems without microarrays, micropores or pillar arrays. | 10-30-2014 |
20140332386 | Method of Building Massively-Parallel Ion Concentration Polarization Separation Device - Ion Concentration Polarization (ICP) purification devices and methods for building massively-parallel implementations of the same, said devices being suitable for separation of salts, heavy metals and biological contaminants from source water. | 11-13-2014 |
20140374274 | Water Desalination/Purification and Bio-Agent Preconcentration by Ion Concentration Polarization - Between two juxtaposed similar ion exchange membranes (AEMs or CEMs), an ion depletion zone (d | 12-25-2014 |
Patent application number | Description | Published |
20080234304 | N3-Pyridyl-Thiamine And Its Use In Cancer Treatments - The invention provides methods using N3-pyridyl-thiamine compounds and pharmaceutical compositions comprising N3-pyridyl-thiamine, which are especially useful for preventing or reducing tumor growth in vivo. The invention is also directed to the benefits of reducing thiamine concentrations, e.g., by means of a thiamine reduced diet, as an effective step in a therapeutic regime for patients treated with N3-pyridyl-thiamine. | 09-25-2008 |
20100173361 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 07-08-2010 |
20100173362 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 07-08-2010 |
20110229462 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 09-22-2011 |
20110236377 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 09-29-2011 |
20120027773 | ANTI-RON ANTIBODIES - Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON. | 02-02-2012 |
20130203963 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 08-08-2013 |
20130203970 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 08-08-2013 |
20140066603 | ANTI-RON ANTIBODIES - Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON. | 03-06-2014 |
20140178934 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 06-26-2014 |
20140178935 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 06-26-2014 |
Patent application number | Description | Published |
20100240879 | PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZENE DERIVATES AND INTERMEDIATES THEREIN - The present invention relates to processes for preparing the compounds of general formula I, | 09-23-2010 |
20100317848 | PROCESS FOR THE SYNTHESIS OF DERIVATIVES OF 3-AMINO-TETRAHYDROFURAN-3-CARBOXYLIC ACID AND USE THEREOF AS MEDICAMENTS - The present invention relates to a process for the manufacturing of substituted 3-amino-tetrahydrofuran-3-carboxylic acid amides of general formula (I) and their precursors in high optical purity to the precursors of the synthesis of substituted S-Amino-tetrahydrofuran-S-carboxylic acid amides of general formula (I) in high optical purity, and to the tautomers, enantiomers, diastereomers, mixtures and salts of substituted 3-amino-tetrahydrofuran-3-carboxylic acid amides of general formula (I) in high optical purity, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties. | 12-16-2010 |
20130005962 | PROCESS FOR THE SYNTHESIS OF DERIVATIVES OF 3-AMINO-TETRAHYDROFURAN-3-CARBOXYLIC ACID AND USE THEREOF AS MEDICAMENTS - The present invention relates to a process for the manufacturing of substituted 3-amino-tetrahydrofuran-3-carboxylic acid amides of general formula (I) and their precursors in high optical purity to the precursors of the synthesis of substituted S-Amino-tetrahydrofuran-5-carboxylic acid amides of general formula (I) in high optical purity, and to the tautomers, enantiomers, diastereomers, mixtures and salts of substituted 3-amino-tetrahydrofuran-3-carboxylic acid amides of general formula (I) in high optical purity, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties. | 01-03-2013 |
20130065904 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders - One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders. | 03-14-2013 |
20140135506 | PROCESS FOR MAKING NOVEL CHIRAL PHOSPHORUS LIGANDS - Disclosed are methods for making chiral phosphorus ligands including chiral phosphines, chiral phosphine oxides, phosphonamides, and aminophosphines. The chiral phosphorus ligands prepared by the methods of the invention are useful as components of chiral catalysts, e.g., transition metal complexes. | 05-15-2014 |
20140315910 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders - One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders. | 10-23-2014 |
Patent application number | Description | Published |
20080293726 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders - One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders. | 11-27-2008 |
20120123164 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders - One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders. | 05-17-2012 |
Patent application number | Description | Published |
20130116986 | VISUALIZATION OF DATA DEPENDENCY IN GRAPHICAL MODELS - In an illustrative embodiment, an apparatus, computer-readable media, or method may be configured to suggest determine relationships. Interaction with a block diagram model may include receiving a first portion of a block diagram model. The block diagram model may include a plurality of blocks. Each of the plurality of blocks may represent a set of dynamic equations. The interacting may be performed using the computer. Relationships between a plurality of a synthesized input, a synthesized output, a synthesized state, or a synthesized derivative, may be determined. A determination may be performed for the first portion of the block diagram model. The determining may include determining a block Jacobian pattern of relationships between two or more of an input, an output, a state, or a derivative of a first block of the plurality of blocks in the graphical model. | 05-09-2013 |
20130116987 | BIDOMAIN SIMULATOR - A method, performed by a computer device, may include selecting one or more input and output points in an executable graphical model in a modeling application and simulating the executable graphical model over a plurality of time points. The method may further include generating a time domain response plot for the executable graphical model based on the simulating; obtaining matrices of partial derivatives based no the selected one or more input and output points at particular time points of the plurality of time points; generating a frequency domain response plot for the executable graphical model based on the obtained matrices of partial derivatives; and generating a bidomain simulator user interface, the bidomain simulator user interface including the generated time domain response plot and the generated frequency domain response plot. | 05-09-2013 |
20130116988 | AUTOMATIC SOLVER SELECTION - A method, performed by a computer device, may include receiving a request to automatically select a solver for a simulation of an executable graphical model, determining a Jacobian matrix for the executable graphical model, calculating a stiffness of the executable graphical model based on the determined Jacobian matrix, and determining whether the calculated stiffness is greater than a stiffness threshold. The method may further include automatically selecting an implicit solver as the solver for the simulation, in response to determining that the calculated stiffness is greater than the stiffness threshold, automatically selecting an explicit solver as the solver for the simulation, in response to determining that the calculated stiffness is not greater than the stiffness threshold, and performing the simulation using the selected solver. | 05-09-2013 |
20130116989 | PARAMETER TUNING - A method, performed by a computer device, may include interacting with one or more plots associated with a simulation of an executable graphical model, receiving a selection of one or more target output points associated with the one or more plots; receiving a selection identifying one or more parameters, associated with the one or more plots, of one or more system parameters, associated with the executable graphical model; and generating an inverse parameter Jacobian matrix. The inverse parameter Jacobian matrix may correspond to an inverse of a parameter Jacobian matrix that relates one or more partial derivatives of the one or more system parameters to one or more system equations. The method may further include determining one or more tuning values for the selected one or more parameters based on the generated inverse parameter Jacobian matrix and based on the selected one or more target output points. | 05-09-2013 |
20130198713 | CODE GENERATION FOR CONTROL DESIGN - A method, performed by a computer device, includes obtaining an in-memory representation of computer code from a block step method of an executable model in a modeling application, wherein the computer code in-memory representation includes one or more variables. The method also includes identifying, from the one or more variables, a subset of persistent variables and determining if any of the one or more variables in the subset of persistent variables are state variables. When none of the subset of persistent variables are state variables, a block output method is generated based on the computer code in-memory representation and the one or more variables. When the subset of persistent variables includes a state variable, both the block output method and a block update method are generated based on the computer code in-memory representation and the one or more variables. | 08-01-2013 |
20130326472 | ANALYZING MODEL BASED ON DESIGN INTEREST - A device may obtain a model. The model, when executed, may simulate a behavior of a physical system. A user, such as, for example, an engineer, may specify a design interest for the model. The design interest may be associated with a particular behavior of a portion of the model. The device may analyze the model based on the design interest and may determine, based on analyzing the model, a group of model elements, included in the model, that are related to the design interest. The device may generate, based on the group of model elements, a model slice. When the model slice is executed, a behavior of the model slice may correspond to the particular behavior of the portion of the model. The device may analyze the particular behavior of the portion of the model based on executing the model slice. | 12-05-2013 |
20150095878 | VISUALIZATION OF DATA DEPENDENCY IN GRAPHICAL MODELS - In an illustrative embodiment, an apparatus, computer-readable media, or method may be configured to suggest determine relationships. Interaction with a block diagram model may include receiving a first portion of a block diagram model. The block diagram model may include a plurality of blocks. Each of the plurality of blocks may represent a set of dynamic equations. The interacting may be performed using the computer. Relationships between a plurality of a synthesized input, a synthesized output, a synthesized state, or a synthesized derivative, may be determined. A determination may be performed for the first portion of the block diagram model. The determining may include determining a block Jacobian pattern of relationships between two or more of an input, an output, a state, or a derivative of a first block of the plurality of blocks in the graphical model. | 04-02-2015 |
Patent application number | Description | Published |
20090024051 | Estimation of F-wave times of arrival (TOA) for use in the assessment of neuromuscular function - A method and apparatus for the assessment of neuromuscular function by estimating motor unit F-wave component time of arrival (TOA), comprising: (i) determining and comparing F-wave component features so as to accurately identify individual F-wave components; (ii) repeatedly searching the individual F-wave components and extracting additional individual F-wavelets where possible so as to build a complete F-wave TOA profile; and (iii) computing and reporting TOA results for the assessment of neuromuscular function. | 01-22-2009 |
20100113980 | Hybrid Terrain-Adaptive Lower-Extremity Systems - Hybrid terrain-adaptive lower-extremity apparatus and methods that perform in a variety of different situations by detecting the terrain that is being traversed, and adapting to the detected terrain. In some embodiments, the ability to control the apparatus for each of these situations builds upon five basic capabilities: (1) determining the activity being performed; (2) dynamically controlling the characteristics of the apparatus based on the activity that is being performed; (3) dynamically driving the apparatus based on the activity that is being performed; (4) determining terrain texture irregularities (e.g., how sticky is the terrain, how slippery is the terrain, is the terrain coarse or smooth, does the terrain have any obstructions, such as rocks) and (5) a mechanical design of the apparatus that can respond to the dynamic control and dynamic drive. | 05-06-2010 |
20100114329 | HYBRID TERRAIN-ADAPTIVE LOWER-EXTREMITY SYSTEMS - Hybrid terrain-adaptive lower-extremity apparatus and methods that perform in a variety of different situations by detecting the terrain that is being traversed, and adapting to the detected terrain. In some embodiments, the ability to control the apparatus for each of these situations builds upon five basic capabilities: (1) determining the activity being performed; (2) dynamically controlling the characteristics of the apparatus based on the activity that is being performed; (3) dynamically driving the apparatus based on the activity that is being performed; (4) determining terrain texture irregularities (e.g., how sticky is the terrain, how slippery is the terrain, is the terrain coarse or smooth, does the terrain have any obstructions, such as rocks) and (5) a mechanical design of the apparatus that can respond to the dynamic control and dynamic drive. | 05-06-2010 |
20110295384 | CONTROLLING POWER IN A PROSTHESIS OR ORTHOSIS BASED ON PREDICTED WALKING SPEED OR SURROGATE FOR SAME - In some embodiments of a prosthetic or orthotic ankle/foot, a prediction is made of what the walking speed will be during an upcoming step. When the predicted walking speed is slow, the characteristics of the apparatus are then modified so that less net-work that is performed during that step (as compared to when the predicted walking speed is fast). This may be implemented using one sensor from which the walking speed can be predicted, and a second sensor from which ankle torque can be determined. A controller receives inputs from those sensors, and controls a motor's torque so that the torque for slow walking speeds is lower than the torque for fast walking speeds. This reduces the work performed by the actuator over a gait cycle and the peak actuator power delivered during the gait cycle. In some embodiments, a series elastic element is connected in series with a motor that can drive the ankle, and at least one sensor is provided with an output from which a deflection of the series elastic element can be determined. A controller determines a desired torque based on the output, and controls the motor's torque based on the determined desired torque. | 12-01-2011 |
20110295385 | CONTROLLING TORQUE IN A PROSTHESIS OR ORTHOSIS BASED ON A DEFLECTION OF SERIES ELASTIC ELEMENT - In some embodiments of a prosthetic or orthotic ankle/foot, a prediction is made of what the walking speed will be during an upcoming step. When the predicted walking speed is slow, the characteristics of the apparatus are then modified so that less net-work that is performed during that step (as compared to when the predicted walking speed is fast). This may be implemented using one sensor from which the walking speed can be predicted, and a second sensor from which ankle torque can be determined. A controller receives inputs from those sensors, and controls a motor's torque so that the torque for slow walking speeds is lower than the torque for fast walking speeds. This reduces the work performed by the actuator over a gait cycle and the peak actuator power delivered during the gait cycle. In some embodiments, a series elastic element is connected in series with a motor that can drive the ankle, and at least one sensor is provided with an output from which a deflection of the series elastic element can be determined. A controller determines a desired torque based on the output, and controls the motor's torque based on the determined desired torque. | 12-01-2011 |
20120259429 | POWERED JOINT ORTHOSIS - A powered device augments a joint function of a human during a gait cycle using a powered actuator that supplies an augmentation torque, an impedance, or both to a joint, and a controller that modulates the augmentation torque, the impedance, and a joint equilibrium according to a phase of the gait cycle to provide at least a biomimetic response. Accordingly, the device is capable of normalizing or augmenting human biomechanical function, responsive to a wearer's activity, regardless of speed and terrain. | 10-11-2012 |
20120259430 | CONTROLLING POWERED HUMAN AUGMENTATION DEVICES - In a communication system for controlling a powered human augmentation device, a parameter of the powered device is adjusted within a gait cycle by wirelessly transmitting a control signal thereto, whereby the adjusted parameter falls within a target range corresponding to that parameter. The target range is selected and the device parameters are controlled such that the powered device can normalize or augment human biomechanical function, responsive to a wearer's activity, regardless of speed and terrain and, in effect, provides at least a biomimetic response to the wearer of the powered device. | 10-11-2012 |
20120259431 | TERRAIN ADAPTIVE POWERED JOINT ORTHOSIS - A powered device augments a joint function of a human during a gait cycle using a powered actuator that supplies an augmentation torque, an impedance, or both to a joint. A controller estimates terrain slope and modulates the augmentation torque and the impedance according to a phase of the gait cycle and the estimated terrain slope to provide at least a biomimetic response. The controller may also modulate a joint equilibrium. Accordingly, the device is capable of normalizing or augmenting human biomechanical function, responsive to a wearer's activity, regardless of speed and terrain, and can be used, for example, as a knee orthosis, prosthesis, or exoskeleton. | 10-11-2012 |
20130312483 | HYBRID TERRAIN-ADAPTIVE LOWER-EXTREMITY SYSTEMS - Hybrid terrain-adaptive lower-extremity apparatus and methods that perform in a variety of different situations by detecting the terrain that is being traversed, and adapting to the detected terrain. In some embodiments, the ability to control the apparatus for each of these situations builds upon five basic capabilities: (1) determining the activity being performed; (2) dynamically controlling the characteristics of the apparatus based on the activity that is being performed; (3) dynamically driving the apparatus based on the activity that is being performed; (4) determining terrain texture irregularities (e.g., how sticky is the terrain, how slippery is the terrain, is the terrain coarse or smooth, does the terrain have any obstructions, such as rocks) and (5) a mechanical design of the apparatus that can respond to the dynamic control and dynamic drive. | 11-28-2013 |
20140081421 | HYBRID TERRAIN-ADAPTIVE LOWER-EXTREMITY SYSTEMS - Hybrid terrain-adaptive lower-extremity apparatus and methods that perform in a variety of different situations by detecting the terrain that is being traversed, and adapting to the detected terrain. In some embodiments, the ability to control the apparatus for each of these situations builds upon five basic capabilities: (1) determining the activity being performed; (2) dynamically controlling the characteristics of the apparatus based on the activity that is being performed; (3) dynamically driving the apparatus based on the activity that is being performed; (4) determining terrain texture irregularities (e.g., how sticky is the terrain, how slippery is the terrain, is the terrain coarse or smooth, does the terrain have any obstructions, such as rocks) and (5) a mechanical design of the apparatus that can respond to the dynamic control and dynamic drive. | 03-20-2014 |
20140081424 | HYBRID TERRAIN-ADAPTIVE LOWER-EXTREMITY SYSTEMS - Hybrid terrain-adaptive lower-extremity apparatus and methods that perform in a variety of different situations by detecting the terrain that is being traversed, and adapting to the detected terrain. In some embodiments, the ability to control the apparatus for each of these situations builds upon five basic capabilities: (1) determining the activity being performed; (2) dynamically controlling the characteristics of the apparatus based on the activity that is being performed; (3) dynamically driving the apparatus based on the activity that is being performed; (4) determining terrain texture irregularities (e.g., how sticky is the terrain, how slippery is the terrain, is the terrain coarse or smooth, does the terrain have any obstructions, such as rocks) and (5) a mechanical design of the apparatus that can respond to the dynamic control and dynamic drive. | 03-20-2014 |
20140088727 | CONTROLLING POWERED HUMAN AUGMENTATION DEVICES - In a communication system for controlling a powered human augmentation device, a parameter of the powered device is adjusted within a gait cycle by wirelessly transmitting a control signal thereto, whereby the adjusted parameter falls within a target range corresponding to that parameter. The target range is selected and the device parameters are controlled such that the powered device can normalize or augment human biomechanical function, responsive to a wearer's activity, regardless of speed and terrain and, in effect, provides at least a biomimetic response to the wearer of the powered device. | 03-27-2014 |
20140114437 | CONTROLLING POWER IN A PROSTHESIS OR ORTHOSIS BASED ON PREDICTED WALKING SPEED OR SURROGATE FOR SAME - In some embodiments of a prosthetic or orthotic ankle/foot, a prediction is made of what the walking speed will be during an upcoming step. When the predicted walking speed is slow, the characteristics of the apparatus are then modified so that less net-work that is performed during that step (as compared to when the predicted walking speed is fast). This may be implemented using one sensor from which the walking speed can be predicted, and a second sensor from which ankle torque can be determined. A controller receives inputs from those sensors, and controls a motor's torque so that the torque for slow walking speeds is lower than the torque for fast walking speeds. This reduces the work performed by the actuator over a gait cycle and the peak actuator power delivered during the gait cycle. In some embodiments, a series elastic element is connected in series with a motor that can drive the ankle, and at least one sensor is provided with an output from which a deflection of the series elastic element can be determined. A controller determines a desired torque based on the output, and controls the motor's torque based on the determined desired torque. | 04-24-2014 |
20140121782 | CONTROLLING TORQUE IN A PROSTHESIS OR ORTHOSIS BASED ON A DEFLECTION OF SERIES ELASTIC ELEMENT - In some embodiments of a prosthetic or orthotic ankle/foot, a prediction is made of what the walking speed will be during an upcoming step. When the predicted walking speed is slow, the characteristics of the apparatus are then modified so that less net-work that is performed during that step (as compared to when the predicted walking speed is fast). This may be implemented using one sensor from which the walking speed can be predicted, and a second sensor from which ankle torque can be determined. A controller receives inputs from those sensors, and controls a motor's torque so that the torque for slow walking speeds is lower than the torque for fast walking speeds. This reduces the work performed by the actuator over a gait cycle and the peak actuator power delivered during the gait cycle. In some embodiments, a series elastic element is connected in series with a motor that can drive the ankle, and at least one sensor is provided with an output from which a deflection of the series elastic element can be determined. A controller determines a desired torque based on the output, and controls the motor's torque based on the determined desired torque. | 05-01-2014 |
20140296997 | BIOMIMETIC TRANSFEMORAL PROSTHESIS - In an artificial limb system having an actuator coupled to a joint for applying a torque characteristic thereto, a control bandwidth of a motor controller for a motor included in the actuator can be increased by augmenting a current feedback loop in the motor controller with a feed forward of estimated back electromotive force (emf) voltage associated with, the motor. Alternatively, the current loop is eliminated and replaced with a voltage loop related to joint torque. The voltage loop may also be augmented with the feed forward of estimated back emf, to improve the robustness of the motor controller. | 10-02-2014 |
20150127118 | PROSTHETIC, ORTHOTIC OR EXOSKELETON DEVICE - A time-dependent decay behavior is incorporated into one or more joint actuator control parameters during operation of a lower-extremity, prosthetic, orthotic or exoskeleton device. These parameters may include joint equilibrium joint impedance (e.g., stiffness, damping) and/or joint torque components (e.g., gain, exponent). The decay behavior may be exponential, linear, piecewise, or may conform to any other suitable function. Embodiments presented herein are used in a control system that emulates biological muscle-tendon reflex response providing for a natural walking experience. Further, joint impedance may depend on an angular rate of the joint. Such a relationship between angular rate and joint impedance may assist a wearer in carrying out certain activities, such as standing up and ascending a ladder. | 05-07-2015 |